Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia
Urodynamic Feasibility Study Utilizing the UroLift® System
UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow, urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test.
- Trial name
- UDS (NCT04271020)
- Testing
- UroLift
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
Prostate
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
- Trial name
- NCT00648323
- Testing
- Doxazosin mysylate GITS
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Prostatic Hyperplasia
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia
- Trial name
- NCT02245555
- Testing
- Tamsulosin
- Volunteers
- 1,060 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia
The primary objective of this trial is to compare the 9-month effect on lower urinary tract symptoms (LUTS) of Prostatic Artery Embolization (PAE) using Embosphere® versus Standard Combined Therapy (alpha-blockers plus 5…
- Trial name
- PARTEM (NCT02869971)
- Testing
- Embosphere® (Prostatic Arteries Embolization), Drug therapy
- Where
- 13 sites in France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002664)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 272 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostate Hypertrophy(BPH)
Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced…
- Trial name
- NCT07017439
- Testing
- Beta-3 agonists (Mirabegron/Myrbetriq)
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Incontinence, Urinary Stress, Prostate Cancer
Effect of Text Message Reminders on M-ISI Score After Prostate Surgery
The purpose of this study is to compare post-prostatectomy incontinence via Michigan Incontinence Score Index in patients receiving daily text message reminders for pelvic floor exercises when compared to those not receiving text…
- Conditions
- Incontinence, Urinary Stress, Prostate Cancer, Benign Prostate Hyperplasia
- Trial name
- TextMsgM-ISI (NCT07071207)
- Testing
- Text message reminders
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- University of Rochester
Benign Prostatic Hyperplasia
Optimized Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia
Water vapor thermal therapy (Rezum) is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation.
- Trial name
- NCT06607094
- Testing
- Rezum
- Volunteers
- 58 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Benign Prostatic Hyperplasia
Minimally Invasive Surgical Therapy for BPH
The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy…
- Trial name
- MIST (NCT00064649)
- Testing
- Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Benign Prostatic Hyperplasia, Stress Urinary Incontinence (SUI)
Optimization of Surgical Treatment Pathways for BPH Based on Real-World Data
Benign prostatic hyperplasia is a noncancerous enlargement of the prostate that can cause difficulty urinating. Holmium laser enucleation of the prostate (HoLEP) uses a laser to remove prostate tissue blocking urine flow.
- Trial name
- NCT07872085
- Testing
- Conventional HoLEP Without Apical Pre-disconnection, HoLEP With Fixed 12 O'clock Apical Pre-disconnection, HoLEP With MRI-Guided Individualized Apical Pre-disconnection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Benign Prostatic Hypertrophy
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00449150
- Testing
- Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg
- Where
- 68 sites in United States, Bulgaria and 2 more
- Volunteers
- 667 people
- Sponsor
- AEterna Zentaris
Urinary Incontinence (UI)
Urinary Incontinence After Endoscopic Prostatectomy
This is a prospective cohort study aiming to identify the preoperative and intraoperative predictors of urinary incontinence after endoscopic transurethral bipolar prostatectomy
- Trial name
- NCT06939140
- Testing
- Bipolar prostatectomy
- Where
- Egypt
- Volunteers
- 133 people
- Sponsor
- Assiut University
Safety, Efficacy
Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH
This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs.
- Conditions
- Safety, Efficacy, Tamsulosin, Monotherapy
- Trial name
- NCT07722884
- Testing
- Tamsulosin 0.4 mg + Tadalafil 2.5 mg, Tamsulosin 0.4 mg + Tadalafil 5 mg, Tamsulosin 0.4 mg
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Benign Prostatic Hyperplasia (BPH)
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00945490
- Testing
- NX-1207
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Benign Prostate Hypertrophy(BPH), Lower Urinary Track Symptoms
Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia
This study compares two FDA-approved surgical treatments for benign prostatic hyperplasia (BPH): Holmium Laser Enucleation of the Prostate (HoLEP) with MOSES 2.0 technology and Robotic Water Jet Ablation (RWJA) using the Hydros…
- Trial name
- NCT07772232
- Testing
- Device - HoLEP with MOSES 2.0, RWJA with Hydros Robotic System
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Methodist Hospital Research Institute
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.
- Trial name
- MCS-2-US-c (NCT01002222)
- Testing
- MCS-2
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Prostatic Hyperplasia, Benign
Prostatic Arterial Embolization With SQUID (Ethylene Vinyl Alcohol Copolymer )
The aim of this pilot study is to analyze the feasibility of prostatic embolization for the treatment of symptomatic benign prostatic hypertrophy with a non adhesive liquid embolic agent (Squid)
- Trial name
- SQUID (NCT05395299)
- Testing
- SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Benign Prostatic Hyperplasia
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224120
- Testing
- Silodosin
- Where
- 42 sites in United States
- Volunteers
- 462 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia (BPH)
The FLOW Registry.
The purpose of this study is to create a database and prospective registry for data collection on patients with benign prostatic hyperplasia undergoing Aquablation of the prostate.
- Trial name
- NCT07430423
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- University of Chicago